What is Multiple Myeloma?
Multiple myeloma, also known as myeloma or Kahler’s disease, is a type of bone marrow cancer. Bone marrow is the spongy tissue at the centre of some bones that produces the body’s blood cells
Early detection of Multiple Myeloma: Serum protein electrophoresis (SPE) is the most common indicator to diagnose and monitor plasma cell myeloma but there are also clinical and biological signs which are indications for SPE such as recurrent infections, hyperviscosity, bone pain or anaemia, renal insufficiency, hypercalcemia.
Multiple myeloma is the 2nd most common blood cancer with more than 160 000 newly diagnosed cases per year, worldwide. Over the past 20 years or so, the annual number of new multiple myeloma patients has increased by 33% due to a growing ageing population.
Diagnosis of Multiple Myeloma
Serum and urine protein electrophoresis and their immunological characterisation are the gold standards for Multiple Myeloma diagnosis, monitoring the disease and assessing the patient’s response to treatment.
Protein electrophoresis is recommended by IMWG (International Myeloma Working Group) for screening serum and urine samples for abnormalities protein detection(3). Once the Monoclonal protein is identified (or suspected), it must be characterized by an immunofixation or immunotyping test to identify the M-Protein type (IgG, IgA, IgM, IgD, IgE) and light chain (kappa or Lambda) involved.
Webinar
Join Sebia, the world leader in the diagnosis and monitoring of Multiple Myeloma on Wednesday 20th April @ 10:00 am CET and or Thursday 21st April @ 4:00 pm CET along with speaker Dr. Julien Guillemaud, PhD, specialist in Hematology and biochemistry, Hospital of Bayonne, France.
In this webinar, thanks to several case reports, Dr. Julien Guillemaud will discuss the importance of SPE for the detection of an M-protein and of serum immunofixation and immunotyping to confirm the presence of the M-protein and determine its isotype. After several general points about SPE and plasma cell myeloma, Dr. Julien Guillemaud will separate his webinar in two parts : abnormal patterns and quantitative abnormalities.
To register click here
to Find out more about our range of Sebia products, click here or contact our product specialists below
